Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

ASTH vs UNH vs CVS vs ALHC

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ASTH
Astrana Health, Inc.

Medical - Care Facilities

HealthcareNASDAQ • US
Market Cap$2.01B
5Y Perf.+33.2%
UNH
UnitedHealth Group Incorporated

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$335.60B
5Y Perf.-0.6%
CVS
CVS Health Corporation

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$111.40B
5Y Perf.+16.1%
ALHC
Alignment Healthcare, Inc.

Medical - Healthcare Plans

HealthcareNASDAQ • US
Market Cap$3.73B
5Y Perf.-16.8%

ASTH vs UNH vs CVS vs ALHC — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ASTH logoASTH
UNH logoUNH
CVS logoCVS
ALHC logoALHC
IndustryMedical - Care FacilitiesMedical - Healthcare PlansMedical - Healthcare PlansMedical - Healthcare Plans
Market Cap$2.01B$335.60B$111.40B$3.73B
Revenue (TTM)$3.53B$449.71B$407.90B$4.26B
Net Income (TTM)$30M$12.04B$2.93B$20M
Gross Margin6.8%18.8%13.9%9.0%
Operating Margin2.5%4.2%1.5%0.8%
Forward P/E29.1x20.2x12.2x140.9x
Total Debt$1.08B$78.39B$93.59B$338M
Cash & Equiv.$429M$24.36B$8.51B$578M

ASTH vs UNH vs CVS vs ALHCLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ASTH
UNH
CVS
ALHC
StockMar 21May 26Return
Astrana Health, Inc. (ASTH)100133.2+33.2%
UnitedHealth Group … (UNH)10099.4-0.6%
CVS Health Corporat… (CVS)100116.1+16.1%
Alignment Healthcar… (ALHC)10083.2-16.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: ASTH vs UNH vs CVS vs ALHC

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: UNH and CVS are tied at the top with 3 categories each — the right choice depends on your priorities. CVS Health Corporation is the stronger pick specifically for valuation and capital efficiency and capital preservation and lower volatility. ASTH also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
ASTH
Astrana Health, Inc.
The Growth Play

ASTH is the clearest fit if your priority is growth exposure and long-term compounding.

  • Rev growth 56.4%, EPS growth -48.9%, 3Y rev CAGR 40.6%
  • 6.1% 10Y total return vs UNH's 220.6%
  • 56.4% revenue growth vs CVS's 7.8%
Best for: growth exposure and long-term compounding
UNH
UnitedHealth Group Incorporated
The Insurance Pick

UNH carries the broadest edge in this set and is the clearest fit for quality and dividends.

  • 2.7% margin vs ALHC's 0.5%
  • 2.4% yield, 25-year raise streak, vs CVS's 3.1%, (1 stock pays no dividend)
  • 3.9% ROA vs CVS's 1.1%, ROIC 9.2% vs 5.0%
Best for: quality and dividends
CVS
CVS Health Corporation
The Insurance Pick

CVS is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.

  • Dividend streak 0 yrs, beta 0.05, yield 3.1%
  • Lower volatility, beta 0.05, current ratio 0.84x
  • Beta 0.05, yield 3.1%, current ratio 0.84x
  • Lower P/E (12.2x vs 140.9x)
Best for: income & stability and sleep-well-at-night
ALHC
Alignment Healthcare, Inc.
The Insurance Play

ALHC lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
See the full category breakdown
CategoryWinnerWhy
GrowthASTH logoASTH56.4% revenue growth vs CVS's 7.8%
ValueCVS logoCVSLower P/E (12.2x vs 140.9x)
Quality / MarginsUNH logoUNH2.7% margin vs ALHC's 0.5%
Stability / SafetyCVS logoCVSBeta 0.05 vs ASTH's 1.11, lower leverage
DividendsUNH logoUNH2.4% yield, 25-year raise streak, vs CVS's 3.1%, (1 stock pays no dividend)
Momentum (1Y)CVS logoCVS+34.7% vs UNH's -3.2%
Efficiency (ROA)UNH logoUNH3.9% ROA vs CVS's 1.1%, ROIC 9.2% vs 5.0%

ASTH vs UNH vs CVS vs ALHC — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

ASTHAstrana Health, Inc.
FY 2025
Health Care Capitation Revenue
91.9%$2.9B
Health Care, Patient Service
3.5%$113M
Health Care, Other
2.7%$86M
Management Service
1.0%$30M
Product and Service, Other
0.9%$28M
UNHUnitedHealth Group Incorporated
FY 2025
Unitedhealthcare
94.4%$332.4B
Optumhealth
5.6%$19.8B
CVSCVS Health Corporation
FY 2025
Pharmacy Revenue
58.9%$229.0B
Premiums
34.6%$134.8B
Front Store Revenue
5.5%$21.5B
Product and Service, Other
1.0%$3.9B
ALHCAlignment Healthcare, Inc.
FY 2023
Health Care, Premium
92.6%$1.7B
Health Care Capitation
7.4%$133M

ASTH vs UNH vs CVS vs ALHC — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLUNHLAGGINGALHC

Income & Cash Flow (Last 12 Months)

UNH leads this category, winning 3 of 6 comparable metrics.

UNH is the larger business by revenue, generating $449.7B annually — 127.5x ASTH's $3.5B. Profitability is closely matched — net margins range from 2.7% (UNH) to 0.5% (ALHC). On growth, ASTH holds the edge at +55.6% YoY revenue growth, suggesting stronger near-term business momentum.

MetricASTH logoASTHAstrana Health, I…UNH logoUNHUnitedHealth Grou…CVS logoCVSCVS Health Corpor…ALHC logoALHCAlignment Healthc…
RevenueTrailing 12 months$3.5B$449.7B$407.9B$4.3B
EBITDAEarnings before interest/tax$141M$23.2B$10.5B$66M
Net IncomeAfter-tax profit$30M$12.0B$2.9B$20M
Free Cash FlowCash after capex$158M$19.7B$7.4B$237M
Gross MarginGross profit ÷ Revenue+6.8%+18.8%+13.9%+9.0%
Operating MarginEBIT ÷ Revenue+2.5%+4.2%+1.5%+0.8%
Net MarginNet income ÷ Revenue+0.9%+2.7%+0.7%+0.5%
FCF MarginFCF ÷ Revenue+4.5%+4.4%+1.8%+5.6%
Rev. Growth (YoY)Latest quarter vs prior year+55.6%+2.0%+6.2%+33.3%
EPS Growth (YoY)Latest quarter vs prior year+107.1%+0.7%+63.1%+2.1%
UNH leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

CVS leads this category, winning 5 of 6 comparable metrics.

At 27.9x trailing earnings, UNH trades at a 64% valuation discount to ASTH's 78.4x P/E. On an enterprise value basis, CVS's 13.1x EV/EBITDA is more attractive than ALHC's 77.1x.

MetricASTH logoASTHAstrana Health, I…UNH logoUNHUnitedHealth Grou…CVS logoCVSCVS Health Corpor…ALHC logoALHCAlignment Healthc…
Market CapShares × price$2.0B$335.6B$111.4B$3.7B
Enterprise ValueMkt cap + debt − cash$2.7B$389.6B$196.5B$3.5B
Trailing P/EPrice ÷ TTM EPS78.43x27.95x62.81x-4932.43x
Forward P/EPrice ÷ next-FY EPS est.29.12x20.19x12.19x140.93x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple21.39x16.70x13.11x77.12x
Price / SalesMarket cap ÷ Revenue0.63x0.75x0.28x0.94x
Price / BookPrice ÷ Book value/share3.19x3.31x1.47x20.16x
Price / FCFMarket cap ÷ FCF19.24x20.88x14.27x32.95x
CVS leads this category, winning 5 of 6 comparable metrics.

Profitability & Efficiency

UNH leads this category, winning 7 of 9 comparable metrics.

UNH delivers a 11.5% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $4 for CVS. UNH carries lower financial leverage with a 0.77x debt-to-equity ratio, signaling a more conservative balance sheet compared to ASTH's 1.93x. On the Piotroski fundamental quality scale (0–9), UNH scores 6/9 vs ASTH's 3/9, reflecting solid financial health.

MetricASTH logoASTHAstrana Health, I…UNH logoUNHUnitedHealth Grou…CVS logoCVSCVS Health Corpor…ALHC logoALHCAlignment Healthc…
ROE (TTM)Return on equity+4.9%+11.5%+3.9%+11.5%
ROA (TTM)Return on assets+1.5%+3.9%+1.1%+1.8%
ROICReturn on invested capital+6.2%+9.2%+5.0%
ROCEReturn on capital employed+6.1%+9.7%+6.1%+2.9%
Piotroski ScoreFundamental quality 0–93656
Debt / EquityFinancial leverage1.93x0.77x1.24x1.89x
Net DebtTotal debt minus cash$649M$54.0B$85.1B-$240M
Cash & Equiv.Liquid assets$429M$24.4B$8.5B$578M
Total DebtShort + long-term debt$1.1B$78.4B$93.6B$338M
Interest CoverageEBIT ÷ Interest expense2.49x4.71x2.11x1.27x
UNH leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — ASTH and CVS and ALHC each lead in 2 of 6 comparable metrics.

A $10,000 investment in CVS five years ago would be worth $11,700 today (with dividends reinvested), compared to $7,726 for ALHC. Over the past 12 months, CVS leads with a +34.7% total return vs UNH's -3.2%. The 3-year compound annual growth rate (CAGR) favors ALHC at 36.2% vs UNH's -7.1% — a key indicator of consistent wealth creation.

MetricASTH logoASTHAstrana Health, I…UNH logoUNHUnitedHealth Grou…CVS logoCVSCVS Health Corpor…ALHC logoALHCAlignment Healthc…
YTD ReturnYear-to-date+43.1%+10.6%+10.6%-9.7%
1-Year ReturnPast 12 months+12.3%-3.2%+34.7%+17.6%
3-Year ReturnCumulative with dividends+3.1%-19.9%+36.6%+152.4%
5-Year ReturnCumulative with dividends+7.8%-2.6%+17.0%-22.7%
10-Year ReturnCumulative with dividends+614.5%+220.6%+3.5%+5.4%
CAGR (3Y)Annualised 3-year return+1.0%-7.1%+11.0%+36.2%
Evenly matched — ASTH and CVS and ALHC each lead in 2 of 6 comparable metrics.

Risk & Volatility

Evenly matched — ASTH and CVS each lead in 1 of 2 comparable metrics.

CVS is the less volatile stock with a 0.05 beta — it tends to amplify market swings less than ASTH's 1.11 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ASTH currently trades 99.7% from its 52-week high vs ALHC's 76.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricASTH logoASTHAstrana Health, I…UNH logoUNHUnitedHealth Grou…CVS logoCVSCVS Health Corpor…ALHC logoALHCAlignment Healthc…
Beta (5Y)Sensitivity to S&P 5001.11x0.59x0.05x0.75x
52-Week HighHighest price in past year$36.20$395.52$88.63$23.87
52-Week LowLowest price in past year$18.08$234.60$58.35$11.63
% of 52W HighCurrent price vs 52-week peak+99.7%+93.5%+98.5%+76.5%
RSI (14)Momentum oscillator 0–10076.875.969.337.3
Avg Volume (50D)Average daily shares traded478K7.9M7.4M3.6M
Evenly matched — ASTH and CVS each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — UNH and CVS each lead in 1 of 2 comparable metrics.

Analyst consensus: ASTH as "Buy", UNH as "Buy", CVS as "Buy", ALHC as "Buy". Consensus price targets imply 36.1% upside for ALHC (target: $25) vs -5.2% for ASTH (target: $34). For income investors, CVS offers the higher dividend yield at 3.06% vs ASTH's 0.44%.

MetricASTH logoASTHAstrana Health, I…UNH logoUNHUnitedHealth Grou…CVS logoCVSCVS Health Corpor…ALHC logoALHCAlignment Healthc…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$34.20$385.43$95.20$24.83
# AnalystsCovering analysts9524116
Dividend YieldAnnual dividend ÷ price+0.4%+2.4%+3.1%
Dividend StreakConsecutive years of raises1250
Dividend / ShareAnnual DPS$0.16$8.70$2.67
Buyback YieldShare repurchases ÷ mkt cap+0.8%+1.7%0.0%0.0%
Evenly matched — UNH and CVS each lead in 1 of 2 comparable metrics.
Key Takeaway

UNH leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CVS leads in 1 (Valuation Metrics). 3 tied.

Best OverallUnitedHealth Group Incorpor… (UNH)Leads 2 of 6 categories
Loading custom metrics...

ASTH vs UNH vs CVS vs ALHC: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is ASTH or UNH or CVS or ALHC a better buy right now?

For growth investors, Astrana Health, Inc.

(ASTH) is the stronger pick with 56. 4% revenue growth year-over-year, versus 7. 8% for CVS Health Corporation (CVS). UnitedHealth Group Incorporated (UNH) offers the better valuation at 27. 9x trailing P/E (20. 2x forward), making it the more compelling value choice. Analysts rate Astrana Health, Inc. (ASTH) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — ASTH or UNH or CVS or ALHC?

On trailing P/E, UnitedHealth Group Incorporated (UNH) is the cheapest at 27.

9x versus Astrana Health, Inc. at 78. 4x. On forward P/E, CVS Health Corporation is actually cheaper at 12. 2x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — ASTH or UNH or CVS or ALHC?

Over the past 5 years, CVS Health Corporation (CVS) delivered a total return of +17.

0%, compared to -22. 7% for Alignment Healthcare, Inc. (ALHC). Over 10 years, the gap is even starker: ASTH returned +614. 5% versus CVS's +3. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — ASTH or UNH or CVS or ALHC?

By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.

05β versus Astrana Health, Inc. 's 1. 11β — meaning ASTH is approximately 2094% more volatile than CVS relative to the S&P 500. On balance sheet safety, UnitedHealth Group Incorporated (UNH) carries a lower debt/equity ratio of 77% versus 193% for Astrana Health, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — ASTH or UNH or CVS or ALHC?

By revenue growth (latest reported year), Astrana Health, Inc.

(ASTH) is pulling ahead at 56. 4% versus 7. 8% for CVS Health Corporation (CVS). On earnings-per-share growth, the picture is similar: Alignment Healthcare, Inc. grew EPS 99. 4% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, ASTH leads at 40. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — ASTH or UNH or CVS or ALHC?

UnitedHealth Group Incorporated (UNH) is the more profitable company, earning 2.

7% net margin versus -0. 0% for Alignment Healthcare, Inc. — meaning it keeps 2. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UNH leads at 4. 2% versus 0. 4% for ALHC. At the gross margin level — before operating expenses — UNH leads at 18. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is ASTH or UNH or CVS or ALHC more undervalued right now?

On forward earnings alone, CVS Health Corporation (CVS) trades at 12.

2x forward P/E versus 140. 9x for Alignment Healthcare, Inc. — 128. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALHC: 36. 1% to $24. 83.

08

Which pays a better dividend — ASTH or UNH or CVS or ALHC?

In this comparison, CVS (3.

1% yield), UNH (2. 4% yield), ASTH (0. 4% yield) pay a dividend. ALHC does not pay a meaningful dividend and should not be held primarily for income.

09

Is ASTH or UNH or CVS or ALHC better for a retirement portfolio?

For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

05), 3. 1% yield). Both have compounded well over 10 years (CVS: +3. 5%, ALHC: +5. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between ASTH and UNH and CVS and ALHC?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ASTH is a small-cap high-growth stock; UNH is a large-cap quality compounder stock; CVS is a mid-cap income-oriented stock; ALHC is a small-cap high-growth stock. UNH, CVS pay a dividend while ASTH, ALHC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

ASTH

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 27%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

UNH

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Dividend Yield > 0.9%
Run This Screen
Stocks Like

CVS

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 1.2%
Run This Screen
Stocks Like

ALHC

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 16%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform ASTH and UNH and CVS and ALHC on the metrics below

Revenue Growth>
%
(ASTH: 55.6% · UNH: 2.0%)
P/E Ratio<
x
(ASTH: 78.4x · UNH: 27.9x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.